RenovoRx, Inc. RNXT
1.66
(0.02)
(1.19%)
as of 25 Sep
- Market cap
- $75.8M
- P/E
- 0.0×
Follow RNXT
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 26.43 | 25.80 | 23.46 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.50) | (9.83) | (10.36) | (16.17) | |
P/B ratio |
5.76 | 5.47 | 3.41 | 5.16 | |
Price to Tangible BV |
5.76 | 5.47 | 3.41 | 5.16 | |
EV/Sales |
0.00 | 24.45 | 20.72 | 21.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.98) | (2.50) | (2.73) | (3.51) | |
EV/FCF |
(3.97) | (2.50) | (2.73) | (3.49) | |
Quick Ratio |
5.42 | 3.65 | 6.58 | 5.29 | |
Current Ratio |
5.83 | 4.02 | 7.15 | 5.74 | |
Net Debt/EBITDA |
3.14 | 1.99 | 3.56 | 2.83 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.14 | 0.10 | 0.16 | |
Operating CF/Net income |
0.78 | 1.03 | 1.05 | 0.98 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (14.20) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
633.46% | 636.97% | 218.12% | 132.01% | |
Selling, General and Administrative Expense of Revenue |
649.62% | 931.09% | 483.13% | 320.68% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
131.20% | 119.75% | 56.31% | 62.71% | |
Graham Net Nets |
0.17 | 0.18 | 0.29 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(28.35%) | (38.10%) | (32.67%) | (31.63%) | |
Free Cash Flow Yield |
(22.34%) | (36.98%) | (29.43%) | (25.75%) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.02 | |
Operating CF per Share |
(0.06) | (0.09) | (0.10) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.09) | (0.10) | (0.06) | |
Cash per Share |
0.27 | 0.20 | 0.33 | 0.20 | |
Shareholders Equity per Share |
0.22 | 0.15 | 0.30 | 0.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.22 | 0.15 | 0.30 | 0.19 | |
Free Cash Flow |
(2.27) | (3.02) | (3.71) | (2.94) | |
Working Capital |
9.10 | 5.93 | 11.80 | 8.93 | |
Capital Expenditures |
0.00 | 0.00 | — | (0.07) | |
Net Current Asset Value |
7.85 | 5.22 | 11.02 | 8.32 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.08 | |
Net Profit Margin |
(1,094.74%) | (1,235.71%) | (625.40%) | (320.24%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.09 | 0.26 | 0.42 | |
Average Payables |
0.78 | 0.69 | 1.04 | 0.77 | |
Average Assets |
10.62 | 8.11 | 14.99 | 12.56 | |
Average Common Equity |
7.57 | 4.95 | 12.21 | 9.81 |
Columns are period end dates